Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

26. Oktober 2018 21:18 ET | Quelle: Retrophin, Inc.

Retrophin Reports Positive Long-Term Data from Open-Label Extension of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis

Increasing achievement of FSGS partial remission of proteinuria and stable eGFR observed out to 84 weeks in open-label extension Findings presented at ASN Kidney Week 2018 SAN DIEGO, Oct. 26,...
25. Oktober 2018 16:01 ET | Quelle: Retrophin, Inc.

Retrophin Announces Publication of Phase 2 DUET Study of Sparsentan for the Treatment of Focal Segmental Glomerulosclerosis in the Journal of the American Society of Nephrology

DUET publication highlighted during Best of ASN Journals session at ASN Kidney Week 2018 SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the Journal...
05. Oktober 2018 16:01 ET | Quelle: Retrophin, Inc.

Retrophin to Present Long-Term Data from Phase 2 DUET Study of Sparsentan in FSGS at ASN Kidney Week 2018

SAN DIEGO, Oct. 05, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data examining the long-term effects of sparsentan in focal segmental...